HIV-Associated Lipodystrophy Treatment Market Size is valued at USD 176.82 Mn in 2023 and is predicted to reach USD 239.62 Mn by the year 2031 at a 4.05% CAGR during the forecast period for 2024-2031.
HIV-associated lipodystrophy is an unfavourable side effect of antiretroviral therapy (ART). Lipodystrophy, often HIV-associated lipodystrophy, is a disease unique to HIV-positive people. Facial, gluteal, thigh, and limb subcutaneous fat all diminish. HIV-infected persons taking antiretroviral medicines have been linked to an increased risk of developing HIV-associated lipodystrophy, albeit these findings have not been replicated across the board. The face, thighs, upper arms, and lower legs are vulnerable to lipoatrophy.
Truncal lipohypertrophy, on the other hand, can cause various symptoms, including belly fat, breast enlargement, a floppy neck, and even lipomas. Facial lipoatrophy, in particular, has been related to low mood, low self-esteem, sexual dysfunction, and social isolation, which can devastatingly affect a patient's well-being and mobility and adhere to antiretroviral therapy (ART). Furthermore, the increased risk of cardiovascular disease is just one way lipodystrophy contributes to morbidity. Other ways include the development of insulin resistance, hyperlipidemia, and endothelial dysfunction. This highlights the critical nature of early diagnosis and treatment for HIV-related lipodystrophy.
However, the market growth is hampered by the lack of knowledge of the safety and health of the HIV-associated lipodystrophy treatment market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity HIV-associated lipodystrophy treatment, a lack of a solid foundation for the control programs; problems with drug availability; a lack of patient commitment to treatment; the presence of co-morbidities and opportunistic infections.
Patients may stop taking their HIV medication because they are afraid of developing lipodystrophy or because they worry that having lipodystrophy will make their HIV status clear to doctors. COVID-19 vaccinations are safe for use in HIV patients. Clinical studies of the COVID-19 vaccine were conducted on people living with HIV. The vaccinations against COVID-19 are safe, productive, and of high enough quality to be approved by the FDA. Diseases are monitored and prevented by the (CDC) reports. There is no evidence that the COVID-19 vaccination is incompatible with HIV treatment or prevention drugs.
Competitive Landscape
Some Major Key Players In The HIV-Associated Lipodystrophy Treatment Market:
- Theratechnologies Inc.
- GlaxoSmithKline plc
- Novelion Therapeutics Inc.
- AstraZeneca plc
- AbbVie Inc.
- Bristol-Myers Squibb
- Amryt Pharmaceuticals, Inc.,
- Fawn Incorporation,
- Abbott Healthcare Solutions,
- Lupin Pharmaceuticals, Inc.,
- Pfizer Inc.,
- Bayer Inc.,
- Novartis Pharmaceuticals Corporation,
- Galderma Laboratories, L.P.
- Others
Market Segmentation
The HIV-Associated Lipodystrophy Treatment Market is segmented based on lipodystrophy type, therapeutic class, and distribution channel. Based on lipodystrophy type, the market is segmented into lipoatrophy and lipoaccumulation. By therapeutic class, the market is segmented into anabolism modulators, Growth hormones, anabolic steroids, insulin resistance modulators, metformin, thiazolidinediones, mitochondrial antioxidants (l-carnitine), and other miscellaneous metabolic agents. The distribution channel segment is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Based On The Therapeutic Class, The Growth Hormones HIV-Associated Lipodystrophy Treatment Market Segment Is Accounted As A Major Contributor To The HIV-Associated Lipodystrophy Treatment Market.
The growth hormones HIV-associated lipodystrophy treatment is expected to lead with a significant global market share in 2024. Growth hormone's functions include affecting height and assisting in bone and muscular development. Growth hormone levels vary naturally throughout the day, seemingly in response to levels of physical exertion.
Online Pharmacy Segment To Witness Growth At A Rapid Rate.
The online pharmacy administration system is designed to remove physical constraints. It paves the way for telehealth services, allowing pharmacists to assist patients physically distant from them, facilitate remote order processing, and introduce new avenues for patient connection, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American HIV-Associated Lipodystrophy Treatment Market Holds A Significant Revenue Share.
The North American HIV-associated lipodystrophy treatment market is expected to record the maximum market share in revenue in the near future. It can be attributed to the good terms of the insurance coverage. Insurance coverage for the treatment of HIV drug side effects such as HIV-related lipodystrophy was recently granted by both the Massachusetts House and Senate. The market for treatments for HIV-related lipodystrophy is anticipated to flourish due to the acceptance of such insurance coverage. In addition, Asia Pacific is estimated to grow rapidly in the global HIV-associated lipodystrophy treatment market because of a confluence of factors that emphasize the importance of a shift in perspective, improved access to care, and a heightened sense of patient agency. An ageing population and a growth in the prevalence of chronic diseases have raised the profile of advanced care planning in the region.
HIV-Associated Lipodystrophy Treatment Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 176.82 Mn |
|
Revenue Forecast In 2031 |
USD 239.62 Mn |
|
Growth Rate CAGR |
CAGR of 4.05% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
by Lipodystrophy Type, by Therapeutic class, by Distribution Channels |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb, Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., Novartis Pharmaceuticals Corporation, Galderma Laboratories, L.P., and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
